肺动脉高压治疗中右心室-肺动脉耦联与舒张功能反应
本研究纵向评估52例初治晚期肺动脉高压患者,在基线和两次随访时用导管及心脏影像评估右心室适应。结果显示基线Ees/Ea不能预测超级反应者,而基线右心室射血分数和Eed早期变化可预测治疗反应。
要点
- 基线Ees/Ea不能区分不可逆右心衰竭的非反应者
- 基线右心室射血分数可预测随访2的超级反应者状态
- Eed早期变化是治疗反应的最佳预测指标之一
核心结论
- 在晚期肺动脉高压患者中,右心室-肺动脉耦联不能区分基线时的不可逆右心衰竭,但随访2时显示改善趋势。
- 基线右心室射血分数和Eed早期变化是治疗反应的最佳预测指标。
研究设计与样本
- 纵向评估52例初治晚期肺动脉高压患者,在基线、随访1(约3个月)和随访2(约18个月)进行导管及心脏影像评估。
- 所有患者接受目标导向治疗,包括肠外曲前列尼尔和/或联合治疗,若未达到功能I或II级则升级治疗。
主要发现
- 9例患者(17%)为非反应者(死亡)。
- PAH导向治疗使欧洲呼吸学会低风险评分从基线1例(2%)提高到随访2的23例(55%)。
- 基线Ees/Ea在反应者(0.9 ± 0.4)与非反应者(0.6 ± 0.4)间无显著差异(P = .09),不能预测随访2超级反应者状态(OR,1.40 [95% CI,0.28-7.0];P = .84)。
- 基线右心室射血分数和Eed变化可预测随访2超级反应者状态(OR,1.15 [95% CI,1.0-1.27];P = .009 和 OR,0.29 [95% CI,0.86-0.96];P = .04)。
关键数值与推荐
- 多参数风险基于简化的欧洲呼吸学会/欧洲心脏病学会指南评分。
- 右心室适应通过单搏耦联比(Ees/Ea)评估,舒张功能通过舒张弹性(Eed)评估。
临床怎么用
- 基线右心室射血分数和Eed早期变化可用于预测肺动脉高压患者对治疗的反应。
- Ees/Ea在基线时不宜单独用于区分不可逆右心衰竭。
局限性
- 样本量较小(52例),非反应者事件数少(9例)。
- Ees/Ea预测超级反应者的OR置信区间宽,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiparametric risk assessment is used in pulmonary arterial hypertension (PAH) to target therapy. However, this strategy is imperfect because most patients remain at intermediate or high risk after initial treatment, with low risk being the goal. Metrics of right ventricular (RV) adaptation are promising tools that may help refine our therapeutic strategy. RESEARCH QUESTION: Does RV adaptation predict therapeutic response over time? STUDY DESIGN AND METHODS: We evaluated 52 incident treatment-naive patients with advanced PAH by catheterization and cardiac imaging longitudinally at baseline, follow-up 1 (∼3 months), and follow-up 2 (∼18 months). All patients received goal-directed therapy with parenteral treprostinil and/or combination therapy with treatment escalation if functional class I or II was not achieved. On the basis of their therapeutic response, patients were evaluated at follow-up 1 as nonresponders (died) or as responders, and again at follow-up 2 as super-responders (low risk) or partial responders (high/intermediate risk). Multiparametric risk was based on a simplified European Respiratory Society/European Society of Cardiology guideline score. RV adaptation was evaluated with the single-beat coupling ratio (Ees/Ea) and diastolic function with diastolic elastance (Eed). Data are expressed as mean ± SD or as OR (95% CI). RESULTS: Nine patients (17%) were nonresponders. PAH-directed therapy improved the European Respiratory Society low-risk score from 1 (2%) at baseline to 23 (55%) at follow-up 2. Ees/Ea at presentation was nonsignificantly higher in responders (0.9 ± 0.4) vs nonresponders (0.6 ± 0.4; P = .09) but could not be used to predict super-responder status at follow-up 2 (OR, 1.40 [95% CI, 0.28-7.0]; P = .84). Baseline RV ejection fraction and change in Eed were successfully used to predict super-responder status at follow-up 2 (OR, 1.15 [95% CI, 1.0-1.27]; P = .009 and OR, 0.29 [95% CI, 0.86-0.96]; P = .04, respectively). INTERPRETATION: In patients with advanced PAH, RV-pulmonary arterial coupling could not discriminate irreversible RV failure (nonresponders) at presentation but showed a late trend to improvement by follow-up 2. Early change in Eed and baseline RV ejection fraction were the best predictors of therapeutic response.
引用
- Vanderpool RR, Hunter KS, Insel M, et al. The Right Ventricular-Pulmonary Arterial Coupling and Diastolic Function Response to Therapy in Pulmonary Arterial Hypertension. Chest. 2021. PMID: 34637777. doi:10.1016/j.chest.2021.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。